Medicine and Dentistry
Ovarian Reserve
100%
Malignant Neoplasm
91%
Antral Follicle
54%
Fertility Preservation
49%
Oocyte Cryopreservation
34%
Cancer Therapy
29%
Assisted Reproductive Technology
27%
Menopausal Symptom
27%
Chorionic Gonadotropin
27%
Oocyte
27%
Symptom
27%
Ectopic Pregnancy
24%
Muellerian Inhibiting Factor
24%
Hormone Determination
23%
Spontaneous Abortion
22%
Prospective Cohort Study
21%
Pregnancy
20%
Logistic Regression Analysis
19%
Lifespan
17%
Counseling
17%
Health Care Cost
16%
Prevalence
16%
Quality of Life
15%
Health System
13%
Population and Population Related Phenomena
13%
Lassa Fever
13%
Pediatrics
13%
Paracentesis
13%
Ovarian Hyperstimulation Syndrome
13%
Biological Marker
13%
Awareness
13%
Cardiovascular Risk
13%
Egg Cell
13%
Hormonal Contraception
13%
Sickle-Cell Disease
13%
Follitropin
13%
Inhibin B
13%
Disease
13%
Diethylstilbestrol
12%
Vasomotor
12%
Alkylating Antineoplastic Agent
11%
Cryopreservation
10%
Reproductive Medicine
9%
Cancer Types
7%
Vaginal Dryness
7%
Final Diagnosis
7%
Oncology
6%
Ovarian Tissue Cryopreservation
6%
Population
6%
Medical Care
6%
Keyphrases
Ovarian Reserve
42%
Cancer Survivors
33%
Antral Follicle Count
31%
Oocyte Cryopreservation
27%
Assisted Reproductive Technology
27%
Female Cancer Survivors
27%
Menopausal Symptoms
27%
Chemotherapy
27%
Young Adult Cancer Survivors
27%
Cancer Therapy
25%
Survivors
23%
Sperm Cryopreservation
20%
Reproductive Age
20%
Infertility
20%
Anti-Mllerian Hormone
19%
Quality of Life
16%
Diminished Ovarian Reserve
16%
Counseling
16%
Women of Reproductive Age
16%
Pregnancy of Unknown Location
16%
Reproductive Lifespan
15%
Health Systems
13%
Spontaneous Preterm Birth (sPTB)
13%
Hormonal Contraception
13%
Egg Freezing
13%
Oocyte Freezing
13%
Spontaneous Ovarian Hyperstimulation Syndrome
13%
Lassa Fever
13%
Rate of Change
13%
Healthy Women
13%
Pediatric
13%
Large-volume Paracentesis
13%
Young Adult Patients
13%
Reserves Recovery
13%
Technical Risk
13%
Pregnancy after Cancer
13%
Pennsylvania
13%
Predictive Models
13%
Gametes
13%
Differential Rate
13%
Patient Autonomy
13%
Multi-country Study
13%
Fertility Preservation Treatment
13%
Oncofertility
13%
Cardiovascular Risk
13%
Technology Data
13%
Human Chorionic Gonadotropin
13%
Sickle Cell Disease
13%
Risk Consequence
13%
Vasomotor Symptoms
12%